FranceMed Pharma with its solid base in the British Market since 1981 and NHS reimbursable listings, owns Market Leading Ethical/OTC brands with unique attributes and is active in Class IIa Therapeutic Medical Devices: Discovery /R&D /Synthesis /Screening /Pre-Clinical /Clinical Phase I, II & III Studies / Manufacturing/ Marketing /Sales Registration and Global Out-licensing.
Its patented micro-fine sprays are classified as Discovery/Greenfield with No Competition, No Me-Toos and No Generics. The products range treat conditions in Dermatology, Paediatrics, Gynaecology, Ophthalmology, Oncology, Neurology, First Aid and Veterinary. The unique sprays treat within seconds mild to severe itch, pain, swelling, burning, stinging, weals,,etc. Repeat use is clinically proven to treat the underlying conditions. FranceMed is certified to ISO 13485 and holds an EC Certificate.
The micro-fine, patented sprays have the following unique attributes:
1) Discovery/Greenfield Medical Devices. 2) Game Changing, Disruptive Technology. 3) Patented. 4) Instant treatment of mild to severe symptoms including itch, pain, stinging, burning, weals, inflammation...etc. 5) Repetitive use is clinically proven to treat the underlying conditions. 6) Captures both the Ethical and OTC Markets. 7) Unique proposition. 8) Safe for all ages including children from birth and pregnant women. 9) Therapeutic Class IIa medical device, hence faster, simpler registration process while avoiding the drugs price fixing by some overseas Health Authorities. 10) Easy to apply micro-fine sprays especially on the whole body or large areas of the skin. 11) Majority of patients find the micro-fine sprays convenient to apply hence satisfaction rate among doctors and patients is high and repeat purchase is phenomenal. 12) Clinically proven. 13) Manufactured in the UK with no direct competition. 14) Hailed by KOLs and physicians as the long awaited topical spray treatment, enquiring from medical reps “why it took so long to reach the market?” 15) No adverse events during pre-market clinical phase or post-market phase.
The micro-fine topical sprays were developed over the last two decades and recently left the R&D pipeline. Successfully launched in the UK and some Export markets. In the UK, its leading brands are market leaders and are available from doctors via the NHS prescription re-imbursement scheme, major chemists and supermarkets. www.francemedpharma.com (includes video describing the New Delivery Technology).
The New Delivery Technology:
FMs unique “Instant T-CNS Signalling System”™ new delivery technology allows a number of stimuli: Thermal (Cooling), Mechanical (Melzack Gate signalling) and Chemical (Synthesis) to be applied topically and simultaneously on the affected areas achieving instant results and greater efficacy than when applying each stimulus in turn. Such stimuli, acting collectively, are a powerful therapeutic tool, as millions of signals are communicated transcutaneously via neurotransmitters (A fibres) to the CNS which instantly trigger the effective treatment of the symptoms and underlying conditions, through repetitive use.
For example, the Dermatological micro-fine sprays for adults and children are clinically proven to safely replace the need for steroids, antihistamines, emollients, pain killers and calamine lotion collectively, resulting in safer, faster, more effective, convenient and more economical treatment for the patient.
The micro-fine topical sprays ease of use, without touching the affected area and ability to treat large areas of the skin in one swoop resulted in excellent patient compliance. There are no known side effects, whether in the pre-market clinical studies phase or in the post-market phase, when millions of packs were used by patients.
FMs Therapeutic Categories:
Dermatology(7 SKUs) , Paediatrics (9 SKUs), Gynaecology(4 SKUs), Emergency Medicine (3 SKUs), Veterinary (1 SKU). Major Distributors are sought with solid experience in one or more of the above specialties and who are market leaders in their countries. Collaboration based on Transfer Prices or In-Licensing are considered.
Collaborators: Three Big Pharma and reputable distributors in several markets in Europe, Asia and the Middle East.